Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lonidamine: an overview.

B Silvestrini1

  • 1Institute of Pharmacology, University La Sapienza, Rome, Italy.

Seminars in Oncology
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Researchers are exploring new cancer treatments targeting oncogene expressions. Lonidamine, an energolytic agent, shows promise by targeting a specialized cancer cell energy system, improving survival rates in certain tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological properties of 3-phenyl-5beta diethylaminoethyl-1,2,4-oxadiazole.

British journal of pharmacology and chemotherapy·2008
Same author

Action of 5,5-diethyl-1,3-oxazine-2,4-dione (dioxone) on respiration and circulation.

British journal of pharmacology and chemotherapy·2008
Same author

Changes of lipocalin type prostaglandin D-synthase in the seminal plasma of subfertile man.

Research communications in molecular pathology and pharmacology·2002
Same author

Toxicity testing in environmental monitoring: the role of enzymatic biosensors.

Annali dell'Istituto superiore di sanita·2002
Same author

Male fertility: core chemical structure in pharmacological research.

Contraception·2002
Same author

Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition.

Psychopharmacology·2002
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Cancer research is shifting focus from cell duplication to oncogene expressions and cofactors.
  • A new generation of anticancer agents, including tamoxifen and lonidamine, has emerged.
  • Lonidamine's discovery necessitated parallel development of cancer energy system knowledge and pharmacological methods.

Purpose of the Study:

  • To investigate the role of a specialized energy system in cancer cell survival and repair.
  • To evaluate lonidamine as a therapeutic agent targeting this cancer-specific energy system.
  • To assess the impact of lonidamine on disease-free interval and survival in tumor types.

Main Methods:

  • Basic research into cancer energy metabolism, particularly the repair phase post-treatment.

Related Experiment Videos

  • Utilizing lonidamine as both a research tool and therapeutic target.
  • Clinical evaluation of lonidamine's efficacy under specific conditions related to its mode of action.

    • Main Results:

    • Cancer cells activate a specialized energy system during repair after hyperthermia, alkylating agents, and radiation.
    • This system provides a survival advantage to cancer cells but is vulnerable to lonidamine.
    • Lonidamine demonstrated an increase in disease-free interval and survival for certain tumor types.

    Conclusions:

    • Lonidamine targets a vulnerable, cancer-specific energy system crucial for cell repair.
    • Targeting this energy system represents a promising therapeutic strategy in oncology.
    • Optimized use of lonidamine can improve patient outcomes in specific cancer types.